Expert Interview
Digging into the phase 2 IGNAZ clinical trial of Felzartamab in patients with IgAN
Ticker(s): BIIBInstitution: Mass General | Harvard
- Clinical researcher & clinician in academic nephrology practice; Nephrologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.
- Currently manages 8-10 patients with CKD associated pruritus, and 6 patients with C3 glomerulopathy.
- Conducts patient-oriented research in the areas of calciphylaxis, vascular calcification and hyponatremia, has authored over 50 peer-reviewed research articles, and research is funded by organizations including the American Kidney Fund & the National Kidney Foundation.
Can you describe your professional background, clinical practice, and experience managing patients with IgA nephropathy, including the number of patients and their typical characteristics?
Added By: slingshot_insightsHow would you summarize the current treatment landscape for IgA nephropathy, including newly approved therapies, and what is your view on targeting CD38 as a therapeutic mechanism?
Added By: slingshot_insightsWhat are your thoughts on the IGNAZ trial dosing regimen and its feasibility in clinical practice, and how do you interpret the trial data on proteinuria reduction, durability of response, and eGFR trends?
How does Felzartamab compare to alternative therapies like APRIL and BLyS inhibitors or Atacicept in terms of proteinuria reduction, GFR stabilization, and delivery methods?
Added By: slingshot_insightsWhat is your assessment of Felzartamab’s safety profile, including infusion-related reactions and infection risks, and how excited are you about its potential as a therapy for IgA nephropathy?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
